Stability of an extemporaneously prepared thalidomide suspension

American Journal of Health-System Pharmacy

Volumn 69, Issue 1, 2012, Pages 56-58

  Kraft, Shawna ^a   Johnson, Cary E ^b,c   Tyler, Ryan P ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UM ^*  (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d Department of Pharmacy Practice   (United States)

Author keywords

Antineoplastic agents; Chromatography, liquid; Compounding; Concentration; Refrigeration; Stability; Storage; Suspensions; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; DRUG CAPSULE; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PLASTIC BOTTLE; POWDER; PRIORITY JOURNAL; SUSPENSION;

EID: 84855266085     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110105     Document Type: Article

References (12)

1. Franks M, Macpherson G, Figg W. Thalidomide. Lancet. 2004; 363:1802-11. (Pubitemid 38698386)
2. Okafor M. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy. 2003; 23:481-93. (Pubitemid 36384327)
3. Thalomid (thalidomide) package insert. Summit, NJ: Celgene Corporation; 1998.
4. Raab MS, Podar K, Breitkreutz I et al. Multiple myeloma. Lancet. 2009; 374:324-39.
5. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007; 4:37-45. (Pubitemid 46117485)
6. Olguín HJ, Pérez CF, Mendiola BR et al. Extemporaneous suspension of propafenone: attending lack of pediatric formulations in Mexico. Pediatr Cardiol. 2008; 29:1077-81.
7. National Institute of Occupational Safety and Health, Centers for Disease Control and Prevention. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. Appendix A: drugs considered hazardous. www.cdc.gov/niosh/docs/2004-165/2004- 165d.html (accessed 2011 Jul 5).
8. Teo SK, Colburn WA, Tracewell WG et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet. 2004; 43:311-27. (Pubitemid 38534754)
9. Höglund P, Ericksson T, Björkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm. 1998; 26:363-83. (Pubitemid 29153518)
10. Reist M, Carrupt PA, Francotte E et al. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol. 1998; 11:1521-8. (Pubitemid 29013628)
11. Ericksson T, Björkman S, Roth B et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995; 7:44-52.
12. Toraño JS, Verbon A, Guchelaar H. Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999; 734:203-10.